Cargando…

Development of CDK inhibitors as cancer therapeutics

Detalles Bibliográficos
Autor principal:	Lane, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233502/ http://dx.doi.org/10.1186/bcr1081

Ejemplares similares

Developing new treatments for breast cancer
por: Lane, D
Publicado: (2004)

Activation of CDK4 by Tax chemosensitizes p53-mutant cells to DNA damage
por: Semmes, O John, et al.
Publicado: (2014)

Therapeutic potential of histone deacetylase inhibitor for treatment of Niemann-Pick type C1 disease
por: Pipalia, Nina H, et al.
Publicado: (2014)

Development of Bevirimat (PA-457): first-in-class HIV maturation inhibitor
por: Allaway, Graham P
Publicado: (2006)

Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?
por: Plummer, R
Publicado: (2011)

DNA repair and breast cancer: therapeutic opportunities
por: Silver, DP
Publicado: (2011)

International experience of pregnancy outcomes in auto-inflammatory syndromes treated with Interleukin-1 inhibitors
por: Youngstein, T, et al.
Publicado: (2015)

Telomerase: a breast cancer chemopreventive and therapeutic target
por: Shay, JW
Publicado: (2000)

Evolution of aromatase inhibitors as an endocrine treatment for breast cancer
por: Miller, WR
Publicado: (2006)

Interrogating of cancer genomes: towards more profile-based therapeutics
por: Carpten, John David
Publicado: (2012)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

Envisioning new targets and new approaches for molecular-based cancer therapeutics
por: Tainer, JA
Publicado: (2005)

Using magnetic resonance to diagnose breast cancer and predict therapeutic response
por: Nelson, MT
Publicado: (2004)

Therapeutic Strategies
por: Prabhakar, P
Publicado: (2013)

Future therapeutic options
por: Reuser, Arnold
Publicado: (2013)

The Journal of Therapeutic Ultrasound
por: Gedroyc, Wladyslaw, et al.
Publicado: (2015)

MRS2179: a novel inhibitor of platelet function
por: Dunne, H, et al.
Publicado: (2015)

Development of novel oncology biomarkers for cancer
por: Yoganathan, Nathan
Publicado: (2014)

Irisin and the therapeutic benefits of exercise
por: Spiegelman, Bruce M, et al.
Publicado: (2012)

Therapeutic targeting truncated adenomatous polyposis coli (APC) proteins for the selective killing of colorectal cancer cells
por: Zhang, Lu, et al.
Publicado: (2014)

The deficiency of adenosine deaminase type 2-results of therapeutic intervention
por: Ombrello, A, et al.
Publicado: (2015)

Virtual screening for plant PARP inhibitors – what can be learned from human PARP inhibitors?
por: Heym, Peter-Paul, et al.
Publicado: (2012)

Stem cells in human breast development and cancer
por: Wicha, M, et al.
Publicado: (2005)

Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes
por: Wilkie, S, et al.
Publicado: (2008)

Variability of pro-apoptotic properties of cyclooxygenase-2 inhibitors in rheumatoid synovial fibroblasts and cancer cell lines
por: Kawai, S, et al.
Publicado: (2003)

Novel resistance mechanism of HIV-1 To peptide fusion inhibitors
por: Gupta, Nidhi, et al.
Publicado: (2006)

The therapeutic relationship in involuntary inpatient care
por: Katsakou, Christina, et al.
Publicado: (2007)

Chronic natriuretic peptide protein therapeutics
por: Chen, Horng H, et al.
Publicado: (2013)

Tax as a therapeutic target in ATL
por: Dassouki, Zeina, et al.
Publicado: (2015)

Evaluation of source data verification in a multicentre cancer trial (PROTECT)
por: Lane, J Athene, et al.
Publicado: (2013)

Cyclin kinase inhibitors and interferons in lupus
por: Theofilopoulos, A
Publicado: (2003)

Stem cells in normal breast development and breast cancer
por: Wicha, MS, et al.
Publicado: (2003)

Use of mouse models to validate and therapeutically target transforming growth factor beta as an important player in breast cancer progression
por: Wakefield, LM, et al.
Publicado: (2003)

Angiogenesis and arthritis: a potential therapeutic target?
por: Grosjean, J, et al.
Publicado: (2004)

The effectiveness of therapeutic eating disorder groups at Isis
por: Signorini, Rachel, et al.
Publicado: (2015)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

O020 Sleep regularity is a stronger predictor of all-cause mortality than sleep duration or sleep efficiency in ~60 000 UK Biobank participants
por: Windred, D, et al.
Publicado: (2022)

Inhibitors of human immunodeficiency virus type I
por: Hazuda, Daria J
Publicado: (2006)

Signal transduction inhibitors for the treatment of rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2012)

Interleukin-37 as fundamental inhibitor of innate immunity
por: Bufler, P
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7oig3s963j1jvs13equ1dikj6s